CELEXA

Compare CELEXA  to:
Compare
Compare

Generic Name for CELEXA

Citalopram (as HBr) 10mg, 20mg+, 40mg+; tabs (+scored).

Legal Classification:

Rx

Pharmacological Class for CELEXA

SSRI.

Manufacturer of CELEXA

Forest Laboratories

Indications for CELEXA

Depression.

Adult dose for CELEXA

Initially 20mg once daily; after ≥1 week may increase to 40mg once daily; may then increase to 60mg once daily for non-responders or partial responders. Elderly or hepatic impairment: 20mg once daily; may increase to 40mg once daily for nonresponders.

Children's dosing for CELEXA

Not recommended.

Also:

Contraindications for CELEXA

During or within 14 days of MAOIs; do not start an MAOI during or within 14 days of citalopram.

Warnings/Precautions for CELEXA

History of seizures or mania/hypomania. Hepatic or severe renal impairment (CrCl <20mL/min). Altered metabolic or hemodynamic states. Recent MI. Unstable heart disease. Suicidal tendencies. ECT. Avoid abrupt cessation. Reevaluate periodically. Write ℞ for smallest practical amount. Labor & delivery. Pregnancy (Cat.C) (avoid 3rd trimester; see literature for effects on neonate). Nursing mothers: not recommended.

Interactions for CELEXA

MAOIs: see Contraindications. Do not give with escitalopram. May be potentiated by cimetidine, potent inhibitors of CYP3A4 (eg, azole antifungals, macrolides), or potent inhibitors of CYP2C19 (eg, omeprazole). May be antagonized by carbamazepine. Caution with tricyclic antidepressants, lithium, other centrally-acting drugs, oral anticoagulants, NSAIDs, aspirin. Alcohol: not recommended. Increases metoprolol levels. Weakness, hyperreflexia, incoordination with 5-HT1B/1D agonists (eg, sumatriptan).

Adverse Reactions for CELEXA

GI upset, dry mouth, somnolence, insomnia, increased sweating, anorexia, rhinitis, sexual dysfunction, agitation, fatigue, arthralgia, myalgia, hyponatremia, SIADH, abnormal bleeding.

How is CELEXA supplied?

Tabs—100
Soln—240mL

Related Disease:

Depression

Related Resources

FDA warns of aseptic meningitis risk with Lamictal

August 13, 2010

The FDA has informed healthcare professionals and patients that Lamictal (lamotrigine, from GlaxoSmithKline) can cause aseptic meningitis.

Oleptro available for major depressive disorder

August 10, 2010

Labopharm and Angelini announced the launch of Oleptro (trazodone HCl extended-release tablets) for the treatment of major depressive disorder (MDD) in adults.

Phase 3 study of TC-5214 for major depressive disorder (MDD)

June 23, 2010

AstraZeneca and Targacept announced the enrollment of the first patient in their Phase 3 development program for TC-5214 as an adjunct treatment for major depressive disorder (MDD) in patients with an inadequate response to first-line therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin/norepinephrine reuptake inhibitor (SNRI).

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

NDA submitted for vilazodone for major depressive disorder (MDD)

March 23, 2010

Clinical Data Inc. announced that a New Drug Application (NDA) has been submitted to the FDA seeking approval of vilazodone for the treatment of major depressive disorder (MDD).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions